We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+2.21%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$5.06B
AUM Growth
-$395M
Cap. Flow
-$256M
Cap. Flow %
-5.05%
Top 10 Hldgs %
43.96%
Holding
127
New
13
Increased
22
Reduced
22
Closed
13

Top Buys

Rank Stock Value
1
ITGR icon
Integer Holdings
ITGR
+$40.8M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$39.5M
3
EXAS
Exact Sciences
EXAS
+$29.3M
4
ARGX icon
argenx
ARGX
+$22M
5
AMGN icon
Amgen
AMGN
+$21M

Top Sells

Rank Stock Value
1
ALPN
Alpine Immune Sciences Inc
ALPN
+$106M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$104M
3
JANX icon
Janux Therapeutics
JANX
+$60.8M
4
ESPR
Esperion Therapeutics
ESPR
+$36.7M
5
SRRK icon
Scholar Rock
SRRK
+$30.6M

Sector Composition

Rank Sector Weight
1 Healthcare 98.69%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRUS
76
DELISTED
Merus
MRUS
$9.24M 0.18%
+156,100
New +$7.56M
SRRK icon
77
Scholar Rock
SRRK
$5.89B
$8.95M 0.18%
1,074,382
-2,500,250
-70% -$30.6M
TSBX
78
DELISTED
Turnstone Biologics
TSBX
$8.12M 0.16%
3,099,265
– –
PASG icon
79
Passage Bio
PASG
$14.2M
$8.04M 0.16%
506,229
– –
SRPT icon
80
CALL
Sarepta Therapeutics
SRPT
$1.65B
$7.9M 0.16%
+50,000
New +$6.42M
PGNY icon
81
Progyny
PGNY
$2.46B
$7.44M 0.15%
259,900
+146,600
+129% +$4.41M
PFE icon
82
CALL
Pfizer
PFE
$145B
$7M 0.14%
+250,000
New +$6.88M
CCCC icon
83
C4 Therapeutics
CCCC
$387M
$6.99M 0.14%
+1,513,058
New +$9.02M
IMA
84
ImageneBio Inc
IMA
$65.3M
$5.84M 0.12%
294,947
– –
FOLD
85
DELISTED
Amicus Therapeutics
FOLD
$5.66M 0.11%
570,300
– –
KRYS icon
86
Krystal Biotech
KRYS
$10.6B
$5.5M 0.11%
29,966
-7,200
-19% -$1.21M
NSPR icon
87
InspireMD
NSPR
$32.3M
$5.32M 0.11%
2,133,405
– –
CATX icon
88
Perspective Therapeutics
CATX
$322M
$4.91M 0.1%
492,670
-157,910
-24% -$2.28M
GPCR icon
89
Structure Therapeutics
GPCR
$3.37B
$4.91M 0.1%
+125,000
New +$5.13M
NKTX icon
90
Nkarta
NKTX
$154M
$4.73M 0.09%
800,000
– –
PHGE icon
91
BiomX
PHGE
$1.95M
$4.63M 0.09%
72,493
+48,716
+205% +$3.28M
VSTM icon
92
Verastem
VSTM
$520M
$4.56M 0.09%
1,529,115
– –
FATE icon
93
Fate Therapeutics
FATE
$267M
$4.45M 0.09%
1,355,352
– –
XFOR icon
94
X4 Pharmaceuticals
XFOR
$368M
$4.14M 0.08%
237,784
– –
SIBN icon
95
CALL
SI-BONE Inc
SIBN
$809M
$3.23M 0.06%
250,000
– –
MRUS
96
CALL
DELISTED
Merus
MRUS
$2.96M 0.06%
+50,000
New +$2.42M
IVVD icon
97
Invivyd
IVVD
$167M
$2.67M 0.05%
2,425,800
-264,500
-10% -$584K
MIST icon
98
Milestone Pharmaceuticals
MIST
$127M
$2.64M 0.05%
2,000,000
– –
GERN icon
99
CALL
Geron
GERN
$911M
$2.54M 0.05%
+600,000
New +$2.34M
ELEV
100
DELISTED
Elevation Oncology
ELEV
$2.54M 0.05%
941,275
– –
2 3
4
5 6

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q2 2024 Portfolio in Review

As of Q2 2024, OrbiMed held 127 positions worth $5.06B, down 7.2% from $5.46B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

OrbiMed withdrew a net $256M in Q2 2024, closing 13 positions and reducing 22 holdings. Its most notable exit was Alpine Immune Sciences Inc, an estimated $106M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier.

Against the trend, OrbiMed opened a new position in Integer Holdings worth $40.4M.

  • OrbiMed's largest Q2 2024 buy was Integer Holdings: 349,221 shares worth $40.4M.
  • OrbiMed added most to Exact Sciences in Q2 2024, an estimated $29.3M increase.
  • OrbiMed's biggest Q2 2024 reduction was BioMarin Pharmaceuticals, cutting an estimated $104M.
  • OrbiMed fully exited Alpine Immune Sciences Inc in Q2 2024, selling an estimated $106M.
  • OrbiMed's ten largest holdings make up 44% of its $5.06B portfolio in Q2 2024.
  • OrbiMed opened 13 new positions and closed 13 in Q2 2024.
  • OrbiMed's portfolio value fell 7.2% quarter-over-quarter to $5.06B.

Based on OrbiMed's 13F filing for Q2 2024, filed 14 Aug 2024.